

## C(10)–C(19) Bond Cleavage Reaction of 19-Oxygenated Androst-4-ene-3,6-dione Steroids under Various Conditions

Masao NAGAOKA and Mitsuteru NUMAZAWA\*

Tohoku Pharmaceutical University; 4–4–1 Komatsushima, Aoba-ku, Sendai 981–8558, Japan.

Received February 16, 2004; accepted May 21, 2004

**C(10)–C(19) bond cleavage reaction of 19-hydroxy- and 19-oxoandrost-4-ene-3,6,17-triones (5, 6) was explored under various conditions. Treatment of steroids 5 and 6 with KOH in MeOH gave the A-ring aromatized product 6-oxoestrone (11) in a fair yield, respectively, in contrast, the treatment with a weak base yielded 4-methyl steroid 17 (20%) in the case of 19-alcohol 5 or 19-nor- $\Delta^{5(10)}$ -steroid 9 (12–67%) along with compound 11 (6–27%) in the case of 19-aldehyde 6. Reaction of compound 6 with HCl in MeOH produced 3-methyl ethers of 6-oxoestrone and  $\Delta^6$ -estrone, compounds 12 and 14 (*ca.* 20% each). Thus, 6-oxosteroids 5 and 6 showed unique C(10)–C(19) bond cleavage reactions with a base or acid.**

**Key words** aromatase inhibitor; 6-oxoandrostenedione; 19-oxygenated steroid; C(10)–C(19) bond cleavage

The androgen androst-4-ene-3,17-dione (androstenedione, **1**) is converted into the estrogen estrone (**10**) through its 19-hydroxy and 19-oxo derivatives (**2**, **3**) by action of the enzyme aromatase (Fig. 1).<sup>1)</sup> 6-Oxoandrostenedione (**4**) that is clinically used for treatment of estrogen-dependent breast cancer, is one of the earliest discovered suicide substrates of aromatase.<sup>2–4)</sup> The mechanism for aromatase inactivation by inhibitor **4** involves the two initial hydroxylations at the C-19 position, producing the 19-oxo derivative **6** through the 19-hydroxy intermediate **5**, followed by an epoxidation of the 4,5-double bond.<sup>5,6)</sup> In this sequence, a part of the 19-oxo intermediate is aromatized to yield 6-oxoestrone (**11**).<sup>7)</sup> On the other hand, we previously have reported that treatment of the 19-oxygenated steroids with a nucleophile, a thiol compound, gives the corresponding 1,4-Michael adduct, a 4 $\alpha$ -thio analog, respectively, where 5(10)-ene steroid **9**, the C(10)–C(19) bond cleavage reaction product, is also obtained from the 19-oxo steroid **6** in a low yield.<sup>8)</sup> The 1,4-addition reaction does not occur in the reaction with corresponding 6-deoxy steroids **2** and **3**.

Taken together, we were of interest to know effect of introducing a carbonyl group at C-6 of the 19-oxygenated steroids **2** and **3** on the C(10)–C(19) bond cleavage reaction in relation to the biological aromatization. This paper describes reactions of 19-oxygenated 6-oxo steroids **5** and **6** under basic and acidic conditions.

### Results and Discussion

We initially examined the C(10)–C(19) bond cleavage of 19-hydroxy-6-oxo steroid **5** under a basic condition. Treatment of 19-ol **5** with a strong base, KOH, in MeOH at room temperature yielded the aromatized product 6-oxoestrone (**11**) in 65% yield (Fig. 2). In contrast, the treatment with a weak base, NaHCO<sub>3</sub>, in MeOH under reflux produced 4-methyl-6-oxoestrone (**17**) in 20% yield along with the recovered substrate. Although there is no evidence, the production mechanism of compound **17** is thought as follows: migration of the 10 $\beta$ -hydroxy methyl group to the 4 $\beta$ -position, yielding 4 $\beta$ -hydroxymethyl-5(10)-ene-3,6-dione intermediate (**15**), followed by dehydration and a sequential isomerization of the C-4 exocyclic methylene double bond introduced may give the aromatized product **17** (Fig. 2). It is known that in the reaction of a 19-hydroxy steroid having no carbonyl

group at C-6, compound **2**, with the strong base, the aromatized product is not formed but a 19-nor derivative, 4-ene<sup>9)</sup> or 5(10)-ene steroid **7**,<sup>10)</sup> is only produced, indicating that the C-6 carbonyl group plays a critical role in the base-catalyzed aromatization reaction. Treatment of the 19-ol **2** with NaHCO<sub>3</sub> yielded neither the 19-nor steroid **7** nor the aromatized product **10**.

The bond cleavage reaction of 19-al **6** was next studied under various conditions (Table 1). Treatment of compound **6** with a weak base, NaHCO<sub>3</sub> or CH<sub>3</sub>COSK, at room temperature gave 19-nor- $\Delta^{5(10)}$ -compound **9** as the major product (56 or 67%) as well as estrogen **11** (13 or 6%). In the reaction





Fig. 1. Structures of Steroids


\* To whom correspondence should be addressed. e-mail: numazawa@tohoku-pharm.ac.jp

Fig. 2. Reaction of 19-Hydroxy Steroid **5** with a BaseTable 1. C(10)–C(19) Bond Cleavage of 19-Oxo Steroid **6** Under Various Conditions

Entry	Conditions	Product, %		
		Aromatized, <b>11</b> , <b>12</b> , or <b>14</b>	$\Delta^{5(10)}$ <b>9</b>	Hemiacetal <b>13</b>
1	NaHCO <sub>3</sub> –MeOH–r.t. <sup>a)</sup>	23 ( <b>11</b> )	56	—
2	Pyridine–H <sub>2</sub> O–reflux	37 ( <b>11</b> )	22	—
3	MeOH–H <sub>2</sub> O–reflux	18 ( <b>11</b> )	55	—
4	CH <sub>3</sub> COSK–MeOH–r.t.	6 ( <b>11</b> )	67	8
5	NaOH–MeOH–r.t.	93 ( <b>11</b> )	—	—
6	HCl–MeOH–r.t.	18 ( <b>12</b> ), 17 ( <b>14</b> )	—	—

a) r.t.: room temperature.

with CH<sub>3</sub>COSK, 19-hemiacetal **13** (8%) was produced in addition to the two products. The 19-hydrogen atom of compound **13** was observed as a singlet peak at 4.38 ppm in the <sup>1</sup>H-NMR spectrum. This along with the <sup>13</sup>C-NMR spectrum revealed that compound **13** is not a mixture of two stereoisomers at the C-19 position. Semiempirical molecular orbital PM3 calculations indicate that the 19-carbonyl group of steroid **6** favors the over-A-ring conformation among the possible three.<sup>11)</sup> This suggests that the nucleophile methoxide anion would approach the carbonyl carbon from the less hindered over-A-ring side rather than the crowded over-C-ring side, thereby giving stereoselectively (1*S*)-19-hemiacetal **13**, as seen in the NaBH<sub>4</sub> reaction of 19-al **3**.<sup>12,13)</sup> In this reaction, the 1,4-addition product 4 $\alpha$ -acetylthio ether was not isolated, although the reaction with benzylmercaptan gives the addition product 4 $\alpha$ -benzylthio ether as well as compound **9**.<sup>8)</sup> When the 19-al **6** was treated with aqueous pyridine or MeOH under reflux gave the two compounds **9** (12 or

Fig. 3. Aromatization Reaction of  $\Delta^{5(10)}$  Steroid **9** Under a Basic or Acidic Condition

45%) and **11** (27 or 13%) in each case. Treatment of the  $\Delta^{5(10)}$ -steroid **9** with NaOH in MeOH at room temperature afforded the aromatized product **11** in a good yield, suggesting that the aromatization reaction would proceed, at least in part, through the  $\Delta^{5(10)}$ -steroid. Based on the result, it is presumed that the conversion of 19-ol **5** into the aromatized product **11** by treatment with KOH in MeOH, described above, may proceed through 19-al **6** produced by an air-oxidation of 19-ol **5** followed by the C(10)–C(19) bond cleavage. It has previously been reported that treatment of the 6-deoxy derivative **3** with pyridine produces the  $\Delta^{5(10)}$ -derivative **7** but not the aromatized product **10**.<sup>9)</sup> The 6-oxo function would be essential for the aromatization reaction of a 5(10)-en-3-one steroid.

Reaction of 19-al **6** with HCl in MeOH at room temperature gave 3-methyl ether of the aromatized product **11**, compound **12**, as well as  $\Delta^6$ -estrone 3-methyl ether (**14**) in low yields. When  $\Delta^{5(10)}$ -steroid **9** was treated with HCl or *p*-TsOH, the aromatized product **11** was obtained in 16% or 20% yield, but the production of compounds **2** and **14** was not detected by TLC analysis of the reaction products in each case. These results indicate that the  $\Delta^{5(10)}$ -steroid **9** is aromatized to produce compound **11** under not only a basic condition but also an acidic condition and this is not an intermediate in a sequence of the HCl-catalyzed production of compounds **12** and **14** from 19-al **6**. 6-Oxoestrone (**11**) was not converted into the 3-methyl ether **12** or the  $\Delta^6$ -estrone analog **14** by the treatment with HCl in MeOH, indicating that the production of compound **12** or **14** does not proceed through the 6-oxo steroid **11**.

It has previously been reported that the acid-catalyzed C(10)–C(19) bond cleavage reactions of steroidal compounds having a 1,4-dien-3-one or 2,3-dihydroxy-4-ene structure produce the corresponding aromatized products *via* the dienone-phenol and related rearrangements.<sup>16,17)</sup> Since 19-oxygenated compounds **5** and **6** have no such structural feature, a 1,4-dien-3-one or 2,3-dihydroxy-4-ene group, required for the dienone-phenol type rearrangements, it is likely that their aromatization reactions observed in this study would not involve the rearrangements.

The present findings indicate that an introduction of the C-6 carbonyl group into 19-hydroxy and 19-oxo steroids **2** and **3** accelerates and/or gives rise to C(10)–C(19) bond cleavage reactions under acidic and basic conditions, although the exact mechanisms for the cleavage reactions are not clear.

#### Experimental

Melting points were measured on a Yanagimoto melting point apparatus (Kyoto, Japan) and are uncorrected. IR spectra were recorded in KBr pellets for the solid products or in neat forms for the oily products on a Perkin-Elmer FT-IR 1725X spectrophotometer (Norwalk, CT, U.S.A.), and UV spectra were determined in 95% ethanol on a Hitachi 150-20 UV spectrophotometer (Tokyo, Japan). <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were obtained in

CDCl<sub>3</sub> solution with a JEOL GX 400 spectrometer (400 MHz for <sup>1</sup>H and 100.5 MHz for <sup>13</sup>C) (Tokyo, Japan) using tetramethylsilane as an internal standard. High-resolution mass spectra (HR-MS) were determined with a JEOL JMS-DX 303 spectrometer. Thin-layer chromatography (TLC) was performed on E. Merck precoated TLC silica gel plates (silica gel 60F-254, layer thickness 0.25 and 0.5 mm for analytical and preparation use, respectively; Darmstadt, Germany). Column chromatography was conducted with silica gel 60, 70–230 mesh (E. Merck, 70–230 mesh).

19-Hydroxyandrost-4-ene-3,6,17-trione (**5**) and androst-4-ene-3,6,17,19-tetraone (**6**) were synthesized according to the previously reported method.<sup>6)</sup>

**Reaction of 19-Hydroxy Steroid 5 with KOH or NaHCO<sub>3</sub>. (A) Reaction with KOH** A solution of KOH (2.7 g, 49 mmol) in 5 ml of water was added to a solution of compound **5** (50 mg, 0.16 mmol) in 30 ml of MeOH and the mixture was stirred at room temperature for 3.5 h. After this time, the reaction mixture was neutralized with conc. HCl, then, condensed to a small volume and extracted with AcOEt (50 ml×2). The organic layer was washed with saturated NaCl solution and dried (Na<sub>2</sub>SO<sub>4</sub>). After evaporation of the solvent, the residue obtained was subjected to preparative TLC (hexane–AcOEt; 1 : 1). The crude product was recrystallized from acetone to give 6-oxoestrone **11** (29 mg, 65%). mp 246–248 °C (lit.<sup>15)</sup> mp 256–257 °C). <sup>1</sup>H-NMR δ 0.93 (3H, s, 18-Me), 7.10 (1H, dd, *J*=8.6, 2.6 Hz, 2-H), 7.33 (1H, d, *J*=8.6 Hz, 1-H), 7.57 (1H, d, *J*=2.6 Hz, 4-H).

**(B) Reaction with NaHCO<sub>3</sub>** A mixture compound **5** (50 mg, 0.16 mmol), NaHCO<sub>3</sub> (787 mg, 9.37 mmol) and MeOH (30 ml) was heated under reflux for 5 h. After this time, the reaction mixture was poured into water and extracted with AcOEt. The organic layer was washed with water and dried (Na<sub>2</sub>SO<sub>4</sub>). After evaporation of the solvent, the residue obtained was separated by preparative TLC (hexane–AcOEt; 1 : 1). The crude product was recrystallized from acetone to give compound **17** (9 mg, 20%). mp 167–171 °C (decomp.). <sup>1</sup>H-NMR δ 0.92 (3H, s, 18-Me), 2.53 (3H, s, 4-Me), 6.99 (1H, d, *J*=8.4 Hz, 2-H), 7.17 (1H, d, *J*=8.4 Hz, 1-H). <sup>13</sup>C-NMR δ 13.2, 13.6, 21.4, 25.5, 31.2, 35.8, 38.5, 43.0, 45.0, 47.6, 50.6, 119.5, 123.2, 126.0, 132.7, 139.8, 152.9, 199.6, 219.8. UV λ<sub>max</sub> (ε); 260 (6800) and 330 (2400) nm. IR ν<sub>max</sub>; 3400, 1728 and 1676 cm<sup>-1</sup>. HR-MS Found: 298.1567; Calcd for C<sub>19</sub>H<sub>22</sub>O<sub>3</sub>: 298.1565. The starting material **5** was also recovered in 20% yield.

**Reaction of 19-Oxo Steroid 6 under Various Conditions. (A) A Basic Condition** Compound **6** (50 mg, 0.16 mmol) in MeOH (15 ml) or pyridine (7.5 ml) was treated with a base for an appropriate time. The reaction mixture was diluted with AcOEt, washed with saturated NaCl solution and dried (Na<sub>2</sub>SO<sub>4</sub>). After evaporation of the solvent, the product was purified by preparative TLC (hexane–AcOEt; 1 : 1). 1) Reaction with NaOH: 1 mol/l NaOH solution (1.57 ml) was added to a solution of compound **6** in MeOH and the mixture was stirred at room temperature for 2 h. 6-Oxoestrone (**11**) (43 mg, 93%). <sup>1</sup>H-NMR δ 0.93 (3H, s, 18-Me), 7.10 (1H, dd, *J*=8.6, 2.6 Hz, 2-H), 7.33 (1H, d, *J*=8.6 Hz, 1-H), 7.60 (1H, d, *J*=2.6 Hz, 4-H). 2) Reaction with NaHCO<sub>3</sub>: 13.2 mg of NaHCO<sub>3</sub> (0.16 mmol) was added to a solution of compound **6** in MeOH and the reaction mixture was stirred at room temperature for 3.75 h. Compound **11** (5.6 mg, 13%). Estr-5(10)-ene-3,6,17-trione (**9**) (25 mg, 56%), mp 166–168 °C (from acetone) (lit.<sup>14)</sup> mp 167–169 °C). <sup>1</sup>H-NMR δ 0.93 (3H, s, 18-Me), 2.98 and 3.25 (1H each, d, *J*=21.1 Hz, 4-H). 3) Reaction with CH<sub>3</sub>COSK: CH<sub>3</sub>COSK (22.5 mg, 0.197 mmol) was added to a solution of compound **6** and the mixture was stirred at room temperature for 3 h. Compound **11** (2.6 mg, 6%), mp 235–237 °C (from acetone) and compound **9** (30.6 mg, 67%), mp 166–168 °C. (19-S)19-Methoxy-19-hydroxyandrost-4-ene-3,6,17-trione (**13**) (4.3 mg, 8%); mp 98–101 °C. <sup>1</sup>H-NMR δ 0.95 (3H, s, 18-Me), 3.81 (3H, s, 19-OMe), 4.38 (1H, s, 19-CH), 6.08 (1H, d, *J*=0.7 Hz, 4-H). <sup>13</sup>C-NMR δ 13.8, 21.6, 21.8, 29.8, 31.4, 32.8, 35.1, 35.7, 38.1, 47.6, 50.2, 50.9, 52.8, 53.3, 71.7, 129.8, 157.8, 174.2, 198.8, 219.9. UV λ<sub>max</sub> (ε); 237 (7400) nm. IR (KBr) ν<sub>max</sub>; 3391, 1727 and 1684 cm<sup>-1</sup>. HR-MS; 346.1826; Calcd for C<sub>20</sub>H<sub>26</sub>O<sub>5</sub>: 346.1872. 4) Reaction with MeOH or pyridine: 2.5 ml of water was added to a solution of compound **6** in MeOH or pyridine and the mixture was heated under reflux for 9 h, giving compound **11** (12 mg, 27% or 6.0 mg, 13%) and compound **9** (5.5 mg, 12% or 20.5 mg, 45%).

**(B) An Acidic Condition** HCl gas was bubbled for 1 min in a solution of compound **6** (50 mg, 0.16 mmol) in 15 ml of MeOH, and the resulting reaction mixture was allowed to stand at room temperature for 2 d. After this

time, the reaction mixture was diluted with AcOEt, washed with 5% NaHCO<sub>3</sub> solution, NaCl solution, and dried (Na<sub>2</sub>SO<sub>4</sub>). After evaporation of the solvent, the residue obtained was subjected to preparative TLC (hexane–AcOEt; 1 : 1) to give two products. The less polar product was recrystallized from acetone to give 3-methoxyestra-1,3,5(10),6-tetraen-17-one (**14**) (7.8 mg, 17%). mp 117–120 °C. <sup>1</sup>H-NMR δ 0.92 (3H, s, 18-Me), 3.80 (3H, s, 3-OMe), 6.07 (1H, dd, *J*=9.7, 1.6 Hz, 7-H), 6.52 (1H, dd, *J*=9.7, 2.3 Hz, 6-H), 6.67 (1H, d, *J*=2.8 Hz, 4-H), 6.75 (1H, dd, *J*=8.4, 2.8 Hz, 2-H), 7.17 (1H, d, *J*=8.4 Hz, 1-H). <sup>13</sup>C-NMR δ 13.6, 21.5, 23.8, 31.1, 35.7, 38.2, 42.1, 48.5, 48.8, 55.3, 111.9, 112.1, 124.3, 128.6, 130.9, 131.0, 135.3, 158.3, 220.3. UV λ<sub>max</sub> (ε); 226 (27000), 262 (6200) nm. IR (KBr) ν<sub>max</sub> 1736 and 1601 cm<sup>-1</sup>. HR-MS Found 282.16180, Calcd for C<sub>19</sub>H<sub>22</sub>O<sub>2</sub>: 282.16178. The more polar product was recrystallized from acetone to give 3-methoxyestra-1,3,5(10)-triene-6,17-dione (**12**) (8.4 mg, 18%). mp 134–137 °C. <sup>1</sup>H-NMR δ 0.93 (3H, s, 18-Me), 3.85 (3H, s, 3-OMe), 7.13 (1H, dd, *J*=8.4, 2.9 Hz, 2-H), 7.35 (1H, d, *J*=8.4 Hz, 1-H), 7.58 (1H, d, *J*=2.9 Hz, 4-H). <sup>13</sup>C-NMR δ 13.7, 21.3, 25.2, 31.2, 35.7, 39.6, 43.0, 43.2, 47.7, 50.2, 55.5, 109.8, 121.7, 126.6, 133.3, 138.9, 158.3, 197.3, 219.6. UV λ<sub>max</sub> (ε); 222 (20000), 255 (8100), 322 (2900) nm. IR (KBr) ν<sub>max</sub> 1741 and 1672 cm<sup>-1</sup>. HR-MS Found; 298.15690 Calcd for C<sub>19</sub>H<sub>22</sub>O<sub>3</sub>: 298.15590.

**Reaction of Δ<sup>5(10)</sup>-Steroid 9. (A) A Basic Condition** To a solution of **9** (50 mg, 0.175 mmol) in 2.5 ml of MeOH was added 1 mol/l NaOH solution (0.17 ml, 0.174 mmol) and the reaction mixture was stirred at room temperature for 5 h. After the same workup as described above, compound **11** (25 mg, 50%) was obtained.

**(B) An Acidic Condition** 1) Reaction with *p*-TsOH: *p*-TsOH monohydrate (21 mg, 0.11 mmol) was added to a solution of compound **9** (50 mg, 0.175 mmol) in 2.5 ml of acetone and the reaction mixture was stirred at room temperature for 2 d. After the same workup as described above, compound **11** (10 mg, 20%) was obtained. 2) Reaction with HCl: HCl gas was bubbled for 1 min in a solution of compound **9** (50 mg, 0.175 mmol) in 15 ml of MeOH, and the reaction mixture was allowed to stand at room temperature for 2 d. After the same workup as described above, compound **11** (8 mg, 16%) was obtained but the production of the other aromatized products **12** and **14** was not detected by the TLC analysis.

## References

- 1) For a review see: Covey D. F., "Steroid Biosynthesis Inhibitors: Pharmaceutical and Agrochemical Aspects," ed. by Berg D., Plemel M., Ellis Horwood Ltd., Chichester, 1988, pp. 534–571.
- 2) Schwarzel W. C., Kruggel W., Brodie H. J., *Endocrinology*, **92**, 866–880 (1973).
- 3) Covey D. F., Hood W. F., *Endocrinology*, **108**, 1597–1599 (1981).
- 4) Numazawa M., Tsuji M., Mutsumi A., *J. Steroid Biochem.*, **28**, 337–344 (1987).
- 5) Numazawa M., Midzuhasi K., Nagaoka M., *Biochem. Pharmacol.*, **47**, 717–726 (1994).
- 6) Numazawa M., Mutsumi A., Tachibana M., *Biochem. Pharmacol.*, **52**, 1253–1259 (1996).
- 7) Numazawa M., Sugiyama T., Nagaoka M., *Biol. Pharm. Bull.*, **21**, 289–292 (1998).
- 8) Numazawa M., Tachibana M., *Steroids*, **58**, 423–428 (1993).
- 9) Hagiwara H., Noguchi S., Nishikawa M., *Chem. Pharm. Bull.*, **8**, 84–85 (1960).
- 10) Barber G. W., Ehrenstein M., *J. Org. Chem.*, **20**, 1253–1259 (1955).
- 11) Numazawa M., Oshibe M., *Biol. Pharm. Bull.*, **18**, 782–784 (1995).
- 12) Osawa Y., Shibata K., Rohrer D., Weeks C., Duax W. L., *J. Am. Chem. Soc.*, **97**, 4400–4402 (1975).
- 13) Numazawa M., Sohtome S., Nagaoka M., *Chem. Pharm. Bull.*, **52**, 722–726 (2004).
- 14) Numazawa M., Oshibe M., Matsuzaki H., *Steroids*, **58**, 423–428 (1993).
- 15) Yoshizawa I., Kamiya E., Itoh S., *Yakugaku Zasshi*, **101**, 285–290 (1981).
- 16) Kirk P. N., Hartshorn M. P., "Steroid Reaction Mechanisms," Chap. 5, Elsevier Publishing Company, Amsterdam, 1968, pp. 277–290.
- 17) Kitagawa I., Nakanishi T., Morii Y., Yoshioka I., *Chem. Pharm. Bull.*, **25**, 2343–2349 (1977).